Summary of TRAEs
| All patients (N=36) | |
| TRAEs | |
| Any grade | 36 (100.0%) |
| Grade 3 | 17 (47.2%) |
| Grade 4 | 5 (13.9%) |
| Serious | 7 (19.4%) |
| TRAEs leading to | |
| Camrelizumab interruption | 14 (38.9%) |
| Camrelizumab discontinuation | 1 (2.8%) |
| Famitinib dose reduction/interruption | 21 (58.3%) |
| Famitinib interruption | 20 (55.6%) |
| Famitinib dose reduction | 9 (25.0%) |
| Famitinib discontinuation | 1 (2.8%) |
| Deaths | 1 (2.8%) |
| Common TRAEs* | Any grade | Grade 3 | Grade 4 |
| Proteinuria | 25 (69.4%) | 2 (5.6%) | 0 |
| Platelet count decreased | 24 (66.7%) | 5 (13.9%) | 2 (5.6%) |
| Anemia | 20 (55.6%) | 3 (8.3%) | 0 |
| PPE syndrome | 15 (41.7%) | 3 (8.3%) | 0 |
| WBC count decreased | 15 (41.7%) | 1 (2.8%) | 0 |
| Hypertension | 13 (36.1%) | 5 (13.9%) | 0 |
| Blood creatinine increased | 11 (30.6%) | 0 | 1 (2.8%) |
| Neutrophil count decreased | 11 (30.6%) | 1 (2.8%) | 0 |
| Diarrhea | 11 (30.6%) | 1 (2.8%) | 0 |
| ALT increased | 10 (27.8%) | 1 (2.8%) | 0 |
| Asthenia | 10 (27.8%) | 0 | 0 |
| AST increased | 9 (25.0%) | 0 | 0 |
| Decreased appetite | 9 (25.0%) | 0 | 0 |
| Hyperuricemia | 7 (19.4%) | 1 (2.8%) | 2 (5.6%) |
| GGT increased | 7 (19.4%) | 2 (5.6%) | 0 |
| Hypertriglyceridemia | 6 (16.7%) | 1 (2.8%) | 0 |
| RCEP | 6 (16.7%) | 1 (2.8%) | 0 |
| Blood pressure increased | 6 (16.7%) | 0 | 0 |
| Hypokalemia | 4 (11.1%) | 2 (5.6%) | 0 |
Data are shown in n (%).
*TRAEs of all grades occurring in at least 15% of patients, grade 3 TRAEs occurring in at least 5% of patients, and all grade 4 TRAEs are listed. One patient died due to TRAE, multiple organ dysfunction syndrome.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; PPE, palmar-plantar erythrodysesthesia; RCEP, reactive capillary endothelial proliferation; TRAE, treatment-related adverse event; WBC, white blood cell.